Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Pennridge SD told to expect ~15% rise in health plan rates as GLP‑1 drug costs spike
Summary
A Conrad Siegel consultant told Pennridge SD committees that rising medical and prescription claims — led by GLP‑1 anti‑obesity drugs — are driving a preliminary 15% plan‑rate projection for FY2627, with targeted mitigations including an upcoming medical RFP and an FSA vendor change.
Mister Pine of consultancy Conrad Siegel told Pennridge SD committee members that the district’s medical and prescription claims have risen sharply in recent years and that preliminary modeling points to roughly a 15% increase in plan rates for FY2627.
"We saw a 15 and a half percent claim increase in 23‑24, about a 9% increase last year in 24‑25, and right now through 25‑26 we're seeing about a 12% increase on that PEPM number," Pine said in the benefits presentation. He attributed much of the recent upward pressure to new prescription drugs for diabetes and anti‑obesity treatment (GLP‑1 medications), which he said have grown “threefold” in recent plan years and now involve more than 100 members on the drugs, up from roughly 10–15 members…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
